Lysis

Genetic Analysis Systems Enter the Clinical Mainstream

Like many other diagnostic regimes that were previously restricted to large specialty laboratories, genetic analysis is entering the clinical mainstream. Smaller, simpler analyzer systems are now suitable and affordable for hospital or large physicians group labs, while some genetic test kits are becoming available for primary point of care locations such as clinics and physician offices.<...

Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing

Since the first system was invented in 1957, blood gas analysis has revolutionized clinical medicine and patient care. During the 1960s, blood gas analysis became almost universally available, and blood gases were considered "the most important laboratory test for critically ill patients," according to a www.bloodgas.or...

Urinalysis Analyzers: Large Capabilities in Every Size Device

Urine chemistry analysis, often conducted in a physicians office practice, can be instrumental in the detection of a wide array of ailments; UTIs, diabetes, several cancers, metabolic disorders, cardiovascular and kidney diseases. The estimated global market for urinalysis tests is well in excess of $600 million per year and is growing strongly. For such a fundamental, extensive and economic...

Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal

LIVINGSTON, N.J.--(BUSINESS WIRE)--Jun 25, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) announced today that an interimanalysis of a pregnancy study comparing the efficacy of CRINONE(R)8% (progesterone gel) to compounded intramuscular progesterone(IMP) injections is now available online and will be published inFertility and Sterility, the journal of the American Society forReproductive...

Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Women's Health Initiative Data

Fourth Study to Indicate that Early Use of Estrogen May beCardio-Protective PHOENIX, June 20, 2007 /PRNewswire-USNewswire/ -- A new analysisof Women's Health Initiative data published in the New EnglandJournal of Medicine, shows significant reduction in calcifiedplaque for women aged 50 to 59 using hormone therapy (HT) comparedwith women taking a placebo. This is the first time therelati...

New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jun 21, 2007 - BioSantePharmaceuticals, Inc. (AMEX:BPA) today provided comment on theWomen's Health Initiative (WHI) Coronary Artery Calcium Studypublished yesterday in The New England Journal of Medicine (NEJM).The study found that younger menopausal women (aged 50-59) whoreceived a standard dose of estrogen therapy had significantly lesscoronary artery...

Haemacure Announces Preliminary Findings of its Plasma Discard Analysis

MONTREAL, June 14, 2007 /PRNewswire-FirstCall/ HaemacureCorporation , a Montreal-based specialty biotherapeutics company,today announced the preliminary findings of the content analysis ofone of its plasma discards. Preliminary findings confirm the presence of a number ofproteins and enzymes with applications in significant worldwidemarkets, including albumin, plasmi...

Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits

* Statistically significant reduction in sedation during theearly post-operative period compared to morphine * Statistically significant reduction in nausea in the femalepatient population compared to morphine Cambridge, UK, 8th June 2007 - CeNeS Pharmaceuticals plc (AIM:CEN), the Cambridge based biopharmaceutical company, announcesadditional data from post-hoc analysis of th...

Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers

- Company Planning to Initiate Phase 2 Trials in Colorectal Cancerand in Hormone-Refractory Prostate Cancer in Q307 - SOUTH SAN FRANCISCO, Calif., June 01, 2007/PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , abiopharmaceutical company focused on oncology, today announcedpromising results from an interim safety analysis of two Phase 1dose-escalating trials of picoplatin, a new ge...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

Study highlights importance of antiplatelet therapy compliance NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced results from an analysis of more than 7,000 patients fromits ARRIVE 1 and 2 registries, designed to assess the performanceof the TAXUS(R) Express2(TM) paclitaxel- eluting coronary stentsystem in "real-world" p...

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-yearfollow-up subset analysis presented today as a late-breakingclinical trial at EuroPCR 2007 showed that the CYPHER(R)Sirolimus-eluting Coronary Stent had results comparable to coronaryartery bypass grafting (CABG or bypass surgery) and better outcomesthan bare metal stents (BMS) in diabetic patients with blockages intw...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

HUMIRA Data Showed 57 Percent Reduction in Risk of Hospitalizationfrom Crohn's Disease vs. Placebo at One Year ABBOTT PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced results from a post-hoc analysis of a pivotal studypresented at the Digestive Disease Week annual meeting inWashington, D.C. showing patients with moderate to severely activeCrohn's disease treated wi...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients takingonce-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- Along-term phase III, open-label 12-14 month extension study (303)presented at the British Society of Gastroenterology (BSG) meetingin Glasgow, Scotland in March 2007 showed Shire plc'sLialda(mesalamine) is w...

Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint

COSTA MESA, Calif.--(BUSINESS WIRE)--May 15, 2007 - Synthetic BloodInternational, Inc. (OTCBB:SYBD) today announced positive data froma statistical analysis of its Phase IIa study with Oxycyte(TM) inpatients with traumatic brain injury. In line with preliminarystudy results announced in December 2006, statistical resultsconfirmed that the primary endpoint of increasing patients' oxygentensi...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...

Mircera Effective in Stabilising Haemoglobin Levels in Elderly Patients With Kidney Disease on Dialysis

Findings Illustrate Role of Innovative New Treatment in PopulationMost Affected by Chronic Kidney Disease BASEL, Switzerland, April 23, 2007 /PRNewswire/ -- A new RochePhase III analysis shows once-monthly MIRCERA, a continuouserythropoietin receptor activator, effectively treats renal anaemiain one of the fastest growing groups of patients with chronickidney disease (CKD) -- elderly pati...

Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data

OTTAWA, April 11 /CNW/ - Liponex Inc. (TSX:LPX), abiopharmaceutical company specializing in developing advancedproducts related to High Density Lipoprotein (HDL), often called"good cholesterol," today announced information from furtheranalysis of the Phase I/II Clinical Trial of its lead product,CRD5. CRD5 is being developed for the treatment of dyslipidemia andheart disease. A de...

Affymax Announces Results From Phase 2 Clinical Trial of Hematide for the Treatment of Anemia in Dialysis Patients

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that results available from its Phase2 clinical trial of Hematide(TM) dosed monthly in dialysis patientswere presented this week at the National Kidney Foundation (NKF)2007 Spring Clinical Meeting. The results from thismaintenance-switch trial in patients previously treated withthree-times weekly E...

First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

KANSAS CITY, Mo.--(BUSINESS WIRE)--Apr 11, 2007 - A comparison ofthe long-term economic outcomes of four immunomodulatory drugtherapies combined with symptom management versus symptommanagement alone revealed that COPAXONE(R) (glatiramer acetateinjection) was the most cost-effective treatment strategy forrelapsing-remitting multiple sclerosis (RRMS). The study providesthe first pharmacoecon...

New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy

COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-FirstCall/ --Wyeth Pharmaceuticals, a division of Wyeth , provides comment on are- analysis of pooled data from both hormone therapy arms of theWomen's Health Initiative (WHI) Study published today in theJournal of the American Medical Association. The pooled analysisshowed no apparent increase in coronary heart disease for women whoinitiate...